Ref

References (47)

• View in search results format 
• All Export  Print  E-mail  Save to PDF Create bibliography

1

Busch, W.

Aus der Sitzung der medicinischen

(1867) Berl Klin Wochenschr, 5 (137). Cited 67 times.

2

Hobohm, U.

Fever and cancer in perspective 

(2001) Cancer Immunology, Immunotherapy, 50 (8), pp. 391-396. Cited 66 times.

3

Coley, W.B.

The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases

(1893) Am J Med Sci, 105 (5), pp. 487-511. Cited 504 times.

4

Burnet, M.

Cancer-A Biological Approach* Iii. Viruses Associated With Neoplastic Conditions 

(1957) British Medical Journal, 1 (5023), p. 841. Cited 203 times.

doi: 10.1136/bmj.1.5023.841

• View at Publisher

5

Burnet, M.

Cancer-A Biological Approach I. The Processes Of Control 

(1957) British Medical Journal, 1 (5022), pp. 779-786. Cited 202 times.

doi: 10.1136/bmj.1.5022.779

• View at Publisher

6

Burnet, M.

Concepts of autoimmune disease and their implications for therapy. 

(1967) Perspectives in Biology and Medicine, 10 (2), pp. 141-151. Cited 5 times.

7

Swann, J.B., Smyth, M.J.

Immune surveillance of tumors 

(2007) Journal of Clinical Investigation, 117 (5), pp. 1137-1146. Cited 519 times.

http://www.jci.org/cgi/reprint/117/5/1137

doi: 10.1172/JCI31405

• View at Publisher

8

Brandau, S., Suttmann, H.

Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement 

(2007) Biomedicine and Pharmacotherapy, 61 (6), pp. 299-305. Cited 105 times.

doi: 10.1016/j.biopha.2007.05.004

• View at Publisher

9

Hanahan, D., Weinberg, R.A.

Hallmarks of cancer: The next generation 

(2011) Cell, 144 (5), pp. 646-674. Cited 15587 times.

doi: 10.1016/j.cell.2011.02.013

• View at Publisher

10

Blank, C., Kuball, J., Voelkl, S., Wiendl, H., Becker, B., Walter, B., Majdic, O., (...), Mackensen, A.

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro 

(2006) International Journal of Cancer, 119 (2), pp. 317-327. Cited 191 times.

doi: 10.1002/ijc.21775

• View at Publisher

11

Mcdermott, D.F., Atkins, M.B.

PD-1 as a potential target in cancer therapy 

(2013) Cancer Medicine, 2 (5), pp. 662-673. Cited 119 times.

doi: 10.1002/cam4.106

• View at Publisher

12

Ostrand-Rosenberg, S., Horn, L.A., Haile, S.T.

The programmed death-1 immune-suppressive pathway: Barrier to antitumor immunity 

(2014) Journal of Immunology, 193 (8), pp. 3835-3841. Cited 25 times.

http://www.jimmunol.org/content/193/8/3835.full.pdf+html

doi: 10.4049/jimmunol.1401572

• View at Publisher

13

Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., (...), Nakajima, Y.

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer 

(2007) Clinical Cancer Research, 13 (7), pp. 2151-2157. Cited 353 times.

doi: 10.1158/1078-0432.CCR-06-2746

• View at Publisher

14

Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., Minato, N.

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade 

(2002) Proceedings of the National Academy of Sciences of the United States of America, 99 (19), pp. 12293-12297. Cited 898 times.

doi: 10.1073/pnas.192461099

• View at Publisher

15

Butte, M.J., Keir, M.E., Phamduy, T.B., Sharpe, A.H., Freeman, G.J.

Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses 

(2007) Immunity, 27 (1), pp. 111-122. Cited 587 times.

doi: 10.1016/j.immuni.2007.05.016

• View at Publisher

16

Nishimura, H., Nose, M., Hiai, H., Minato, N., Honjo, T.

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor 

(1999) Immunity, 11 (2), pp. 141-151. Cited 1133 times.

doi: 10.1016/S1074-7613(00)80089-8

• View at Publisher

17

Okudaira, K., Hokari, R., Tsuzuki, Y., Okada, Y., Komoto, S., Watanabe, C., Kurihara, C., (...), Miura, S.

Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model 

(2009) International Journal of Oncology, 35 (4), pp. 741-749. Cited 63 times.

http://www.spandidos-publications.com/serveFile/ijo_35_4_741_PDF.pdf?type=article&article_id=ijo_35_4_741&item=PDF

doi: 10.3892/ijo-00000387

• View at Publisher

18

(2015) 

Bristol-Myers Squibb Company. March. Accessed April 18 2017

http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125527s000lbl.pdf

19

(2016) KEYTRUDA (Pembrolizumab) Prescribing Information. Cited 2 times.

Merck & Co. October. Accessed April 18 2017

http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125514s012lbl.pdf

20

(2017) Tecentriq (Atezolizumab) Prescribing Information

Genentech. Accessed April 18

https://www.gene.com/medical-professionals/medicines/tecentriq

21

Liu, S.V., Giaccone, G.

Atezolizumab in lung cancer-Appreciating the differences 

(2016) Translational Cancer Research, 5, pp. S470-S473.

http://tcr.amegroups.com/article/download/9453/pdf

doi: 10.21037/tcr.2016.09.15

• View at Publisher

22

Selby, M., Engelhardt, J., Lu, L.-S., Quigley, M., Wang, C., Chen, B., Korman, A.J.

Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models

(2013) J Clin Oncol [49th Annu Meet Am Soc Clin Oncol (ASCO), 31. Cited 31 times.

(May 31-June 4, Chicago) 2013] Abst 3061

23

Mizugaki, H., Yamamoto, N., Murakami, H., Kenmotsu, H., Fujiwara, Y., Ishida, Y., Kawakami, T., (...), Takahashi, T.

Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors 

(2016) Investigational New Drugs, 34 (5), pp. 596-603. Cited 4 times.

www.wkap.nl/journalhome.htm/0167-6997

doi: 10.1007/s10637-016-0371-6

• View at Publisher

24

Markham, A.

Atezolizumab: First Global Approval 

(2016) Drugs, 76 (12), pp. 1227-1232. Cited 4 times.

http://rd.springer.com/journal/40265

doi: 10.1007/s40265-016-0618-8

• View at Publisher

25

Mankarious, S., Lee, M., Fischer, S., Pyun, K.H., Ochs, H.D., Oxelius, V.A., Wedgwood, R.J.

The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin 

(1988) Journal of Laboratory and Clinical Medicine, 112 (5), pp. 634-640. Cited 76 times.

26

Ratcliffe, M.J., Sharpe, A., Midha, A., Barker, C., Scorer, P., Walker, J.

A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative

(2016) Cancer Res [107th Annu Meet Am Assoc Cancer Res (AACR), 76 (14). Cited 2 times.

(April 16-20, New Orleans) 2016] Abst LB-094

27

Gibney, G.T., Weiner, L.M., Atkins, M.B.

Predictive biomarkers for checkpoint inhibitor-based immunotherapy 

(2016) The Lancet Oncology, 17 (12), pp. e542-e551. Cited 15 times.

http://www.journals.elsevier.com/the-lancet-oncology/

doi: 10.1016/S1470-2045(16)30406-5

• View at Publisher

28

Herbst, R.S., Soria, J.-C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., (...), Hodi, F.S.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients 

(2014) Nature, 515 (7528), pp. 563-567. Cited 919 times.

http://www.nature.com/nature/index.html

doi: 10.1038/nature14011

• View at Publisher

29

Petrylak, D.P., Powles, T., Bellmunt, J.

A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC)

(2015) J Clin Oncol [51st Annu Meet Am Soc Clin Oncol (ASCO)

(May 29-June 2, Chicago) 2015], Abst 4501

30

Sznol, M., McDermott, D.F., Jones, S.F.

Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab in patients with metastatic renal cell carcinoma (mRCC)

(2015) J Clin Oncol, 33.

[Genitourin Cancers Symp (Feb 26-28, Orlando) 2015]: Abst 410

31

Adams, S., Diamond, J.R., Hamilton, E.P.

Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC)

(2016) J Clin Oncol, 34. Cited 13 times.

[52nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2016]: Abst 1009

32

Bendell, J.C., Kim, T.W., Goh, B.C.

Clinical activity and safety of cobimetinib and atezolizumab in colorectal cancer (CRC)

(2016) J Clin Oncol, 34.

[52nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2016]: Abst 3502

33

Thomas, A., Liu, S.V., Subramaniam, D.S., Giaccone, G.

Refining the treatment of NSCLC according to histological and molecular subtypes 

(2015) Nature Reviews Clinical Oncology, 12 (9), pp. 511-526. Cited 42 times.

http://www.nature.com/nrclinonc/archive/index.html

doi: 10.1038/nrclinonc.2015.90

• View at Publisher

34

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., (...), Brahmer, J.R.

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer 

(2015) New England Journal of Medicine, 373 (17), pp. 1627-1639. Cited 894 times.

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1507643

doi: 10.1056/NEJMoa1507643

• View at Publisher

35

Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Hui, R., Csöszi, T., Fülöp, A., Gottfried, M., (...), Brahmer, J.R.

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer 

(2016) New England Journal of Medicine, 375 (19), pp. 1823-1833. Cited 191 times.

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1606774

doi: 10.1056/NEJMoa1606774

• View at Publisher

36

Spigel, D.R., Chaft, J.E., Gettinger, S.N.

Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small lung cancer (NSCLC)

(2015) J Clin Oncol, p. 33. Cited 29 times.

[51st Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 4, Chicago) 2015]: Abst 8028

37

Besse, B., Johnson, M., Janne, P.A.

Phase II, single arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)

(2015) Eur J Cancer, 51, pp. S717-S718. Cited 17 times.

[Eur Cancer Congr (Sept 25-29, Vienna) 2015]

38

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., (...), Rittmeyer, A.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial 

(2016) The Lancet, 387 (10030), pp. 1837-1846. Cited 208 times.

http://www.journals.elsevier.com/the-lancet/

doi: 10.1016/S0140-6736(16)00587-0

• View at Publisher

39

Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S.M., (...), Gandara, D.R.

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial 

(2017) The Lancet, 389 (10066), pp. 255-265. Cited 32 times.

http://www.journals.elsevier.com/the-lancet/

doi: 10.1016/S0140-6736(16)32517-X

• View at Publisher

40

Von Der Maase, H., Sengelov, L., Roberts, J.T., Ricci, S., Dogliotti, L., Oliver, T., Moore, M.J., (...), Arning, M.

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer 

(2005) Journal of Clinical Oncology, 23 (21), pp. 4602-4608. Cited 700 times.

doi: 10.1200/JCO.2005.07.757

• View at Publisher

41

Loehrer Sr., P.J., Einhorn, L.H., Elson, P.J., Crawford, E.D., Kuebler, P., Tannock, I., Raghavan, D., (...), Trump, D.

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study 

(1992) Journal of Clinical Oncology, 10 (7), pp. 1066-1073. Cited 651 times.

• View at Publisher

42

Sternberg, C.N., Calabrò, F., Pizzocaro, G., Marini, L., Schnetzer, S., Sella, A.

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy 

(2001) Cancer, 92 (12), pp. 2993-2998. Cited 173 times.

doi: 10.1002/1097-0142(20011215)92:12<2993::AID-CNCR10108>3.0.CO;2-2

• View at Publisher

43

Li, J., Juliar, B., Yiannoutsos, C., Ansari, R., Fox, E., Fisch, M.J., Einhorn, L.H., (...), Sweeney, C.J.

Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: A phase II Hoosier Oncology Group study 

(2005) Journal of Clinical Oncology, 23 (6), pp. 1185-1191. Cited 69 times.

doi: 10.1200/JCO.2005.05.089

• View at Publisher

44

Rosenberg, J.E., Hoffman-Censits, J., Powles, T., Van Der Heijden, M.S., Balar, A.V., Necchi, A., Dawson, N., (...), Dreicer, R.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial 

(2016) The Lancet, 387 (10031), pp. 1909-1920. Cited 281 times.

http://www.journals.elsevier.com/the-lancet/

doi: 10.1016/S0140-6736(16)00561-4

• View at Publisher

45

Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., (...), Sznol, M.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer 

(2012) New England Journal of Medicine, 366 (26), pp. 2443-2454. Cited 3731 times.

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1200690

doi: 10.1056/NEJMoa1200690

• View at Publisher

46

Topalian, S.L., Sznol, M., McDermott, D.F., Kluger, H.M., Carvajal, R.D., Sharfman, W.H., Brahmer, J.R., (...), Hodi, F.S.

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab 

(2014) Journal of Clinical Oncology, 32 (10), pp. 1020-1030. Cited 670 times.

http://jco.ascopubs.org/content/32/10/1020.full.pdf+html

doi: 10.1200/JCO.2013.53.0105

• View at Publisher

47

Clinicaltrials.gov

https://clinicaltrials.gov/ct2/results?term=atezolizumab&Search=Search

  Jimeno, A.; Department of Medicine, Division of Medical Oncology, Developmental Therapeutics Program, University of Colorado Cancer Center, PO Box 6511, Aurora, CO, United States; email:Antonio.Jimeno@ucdenver.edu 

© Copyright 2017 Elsevier B.V., All rights reserved.